PAINWeek Conference

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses the most common misconceptions that patients have about pain.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses how compounding pharmacists can help patients with chronic pain.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses the relationship between chronic pain and stress.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses why opioid abuse has become an increasingly urgent issue.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the pharmacist's role in combating the opioid abuse epidemic.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the challenges facing abuse-deterrent opioids as their manufacturers attempt to bring them to market.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the mechanisms by which abuse-deterrent opioids prevent misuse.

In this video from PainWeek 2017, Jeremy Adler, MS, PA-C, co-owner of Pacific Pain Medicine, discusses the benefits of abuse-deterrent opioids.

Patients who were treated by the IPT experienced a 61% greater reduction in morphine equivalent daily dose (MEDD) than those who received usual care group.

In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses treatment options for sleep-related pain.

Insurers can also help address this devastating epidemic.

In response to the growing opioid abuse epidemic, several health groups have written a petition requesting that the FDA remove ultra-high dosage unit (UHDU) analgesics from the market.

Although it's difficult to determine exactly how many patients experience opioid-induced constipation, the large quantities of prescribed opioids in circulation create widespread potential for this bothersome adverse effect.

The opioid overdose death toll has been steadily increasing for more than a decade, making it a leading cause of accidental death in the United States.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacists can help prevent OIC.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses counseling points for OIC patients.

Jeffrey Gudin, MD, outlines the steps pharmacists should take to reduce opioid-induced constipation.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses the latest advancements in OIC treatment.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses potential adverse effects associated with naloxone.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how pharmacy-based OIC care differs from other settings.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system pharmacists can assess patients' risk for opioid overdose.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses OTC recommendations for OIC symptoms.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses how often pharmacists work with OIC patients.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses what pharmacists should tell patients about administering naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses how health-system and community pharmacists can work together to provide naloxone.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses prices of naloxone products.

Jeffrey Gudin, MD, describes the impact of opioid-induced constipation on patients taking opioids.

Mary M. Bridgeman, PharmD, BCPS, CGP, discusses where fiber supplementation fits into OIC care.